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Abstract
Relief from painful diabetic neuropathy is an important clinical issue. We have previously shown that the transplantation of
cultured endothelial progenitor cells or mesenchymal stem cells ameliorated diabetic neuropathy in rats. In this study, we
investigated whether transplantation of freshly isolated bone marrow-derived mononuclear cells (BM-MNCs) alleviates
neuropathic pain in the early stage of streptozotocin-induced diabetic rats. Two weeks after STZ injection, BM-MNCs or
vehicle saline were injected into the unilateral hind limb muscles. Mechanical hyperalgesia and cold allodynia in SD rats
were measured as the number of foot withdrawals to von Frey hair stimulation and acetone application, respectively. Two
weeks after the BM-MNC transplantation, sciatic motor nerve conduction velocity (MNCV), sensory nerve conduction
velocity (SNCV), sciatic nerve blood flow (SNBF), mRNA expressions and histology were assessed. The BM-MNC
transplantation significantly ameliorated mechanical hyperalgesia and cold allodynia in the BM-MNC-injected side.
Furthermore, the slowed MNCV/SNCV and decreased SNBF in diabetic rats were improved in the BM-MNC-injected side. BM-
MNC transplantation improved the decreased mRNA expression of NT-3 and number of microvessels in the hind limb
muscles. There was no distinct effect of BM-MNC transplantation on the intraepidermal nerve fiber density. These results
suggest that autologous transplantation of BM-MNCs could be a novel strategy for the treatment of painful diabetic
neuropathy.
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Introduction
Diabetic neuropathy is the most common complication of diabetes.
The abnormal peripheral sensations (skin or deep tissues) show great
variety, such as paresthesia, allodynia, hyperalgesia, and spontaneous
pain. Especially, chronic neuropathic pain is present in 3 to over 20%
of diabetic patients [1]. Pharmacological treatments such as anti-
depressants and anti-convulsives are effective but the effects are partial
in many cases, and thus many patients have a marked reduction in the
quality of life [2]. The relief from symptoms of diabetic neuropathy is,
therefore, still an important issue for many clinicians.
It has been reported that diabetic animal models show pain-
related behaviors that mimic symptoms of painful diabetic
neuropathy in humans [3]. Hyperalgesic behaviors are observed
in the early stage of diabetes of several animal lines such as
streptozotocin (STZ) diabetic rats and mice, BB/Wor rats, Zucker
diabetic fatty rats, and ob/ob mice [4–6]. Using these animal
models, many studies have been done to understand of the
mechanisms of painful diabetic neuropathy. Treatment with
antioxidants, such as a-lipoic acid [7], taurine [6] and a
poly(ADP-ribose) polymerase (PARP) inhibitor [8], or aldose
reductase inhibitors [9,10] ameliorated mechanical and thermal
hyperalgesia in diabetic rats. Treatment with C-peptide also
improved diabetic mechanical and thermal hyperalgesia, and the
improvement was accompanied by recovery from the morpho-
metric abnormalities and decreased contents of several neuro-
tropic proteins in the peripheral nerves [4]. a-Lipoic acid and an
aldose reductase inhibitor are available for the treatment of
diabetic neuropathy in some countries and some other drugs are in
clinical trials [11], but more powerful therapies are needed for the
treatment of painful diabetic neuropathy not only for the relief
from pain but also to improve nerve functions.
The disturbance of peripheral blood flow is one of the major
pathological causes of diabetic neuropathy [12]. Impairments of
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vasoconstriction, and epineural blood flow in the sural nerve were
observed in diabetic painful neuropathy [13,14]. Several clinical
studies have shown that transplantation of bone marrow-derived
mononuclear cells (BM-MNCs) into the skeletal muscles can be an
effective treatment for ischemic limbs, because it enhances post-
ischemic neovascularization and increases vascular blood flow
[15,16]. The bone marrow is known to contain larger numbers of
progenitor or stem cells such as endothelial progenitor cells and
mesenchymal stem cells than peripheral blood [17,18]. BM-MNCs
secrete potent angiogenic ligands (basic FGF, VEGF, angiopoie-
tin-1) and cytokines (IL-1b and TNF-a), and are also incorporated
into the local neovascularization. A benefit of the transplantation
of freshly isolated MNCs is that autologous MNCs can be isolated
in a closed cavity, not only in ex vivo culture conditions. We have
previously demonstrated that the transplantation of cultured
endothelial progenitor cells or mesenchymal stem cells improved
diabetic neuropathy in STZ rats [19,20]. Transplantation of bone
marrow or peripheral blood MNC also improved the delay of
nerve conduction velocity and nerve blood flow in STZ rats
[21,22]. Taken together, MNCs could be a promising cell source
for the treatment of diabetic neuropathy, including diabetic
hyperalgesia, because of their secretion of angiogenic ligands and
cytokines involved in vasculogenesis. In the present study,
therefore, we examined whether transplantation of freshly isolated
BM-MNCs improved mechanical hyperalgesia and cold allodynia
in STZ diabetic rats. We found, for the first time, that
intramuscular transplantation of BM-MNCs ameliorated the
diabetic neuropathic pain, accompanied with the functional
recovery of the peripheral nerves and increased tissue blood flow.
Methods
Animals
Male Sprague-Dawley (SD) rats were obtained from Japan
SLC, Inc. (Shizuoka, Japan) at 6 weeks of age. All rats were housed
in individual cages under controlled temperature (2461.0uC) and
on a 12 h light/dark cycle, and were given standard laboratory rat
chow with water ad libitum. Diabetes was induced by a single
intraperitoneal injection of freshly dissolved STZ (Sigma Chemical
Co., MO, USA) (60 mg/kg body weight in 0.9% sterile saline) to
rats after an overnight fast. Diabetes was identified by polydipsia,
polyuria and by measuring the non-fasting serum glucose
concentration 1 week after the injection of STZ. Rats with a
blood glucose level above 12.5 mM were considered to be diabetic
and were used in the experiments. Age-matched male SD rats
were used as control animals. All experimental protocols were
conducted according to the Regulations for Animal Experiments
in Nagoya University, and were approved by the Institutional
Animal Care and Use Committees of Nagoya University and
Aichi Gakuin University.
Bone marrow-derived mononuclear cells
Bone marrow was taken from the femoral and tibial bones in 6-
week-old male SD rats and was suspended in phosphate buffered
saline (PBS). BM-MNCs were isolated using the Histopaque-
density centrifugation method. The MNC layer was collected,
washed twice with PBS, and suspended in 0.9% saline with 0.5%
bovine serum albumin (BSA).
Transplantation of BM-MNCs
Two weeks after the STZ injection, the diabetic rats were deeply
anesthetized with pentobarbital (50 mg/kg body weight, intraper-
itoneally) and were transplanted with BM-MNCs into the hind limb
skeletal muscles. The MNC suspension (0.5 ml in total, 1610
6 cells)
was injected into 10 points in the unilateral femoral quadriceps,
femoral biceps and soleus muscles using a 26-gauge needle. Saline
(0.5 ml in total) was also injected into the contralateral hindlimb
skeletal muscles as the control. In some behavioral tests, saline
(0.5 ml in total) was injected into the unilateral hind limb skeletal
muscles in another group of diabetic control rats.
Measurements of nociceptive behaviors
All behavioral tests were performed in a blinded fashion.
Baseline behavioral tests were carried out to assess the degree of
mechanical hyperalgesia and cold allodynia before the STZ
injection, and the same test was repeated at 1–2 weekly intervals
for 4 (mechanical hyperalgesia) to 6 (cold allodynia) weeks,
beginning 2 weeks after STZ injection. Each rat was placed
individually beneath an inverted transparent plastic cage
(11617611 cm) with a wire mesh bottom and habituated to the
test chamber for at least 30 min before the measurements.
1. Mechanical hyperalgesia. Pain-related behavior induced
by mechanical stimulation was measured with two types of
homemade von Frey hairs (VFHs, diameter: 0.5 mm, bending
force 93 and 197 mN). Each VFH was applied perpendicularly ten
times (once every 2–3 sec) to the unilateral mid-plantar hind paw,
and the number of foot withdrawals was then counted. Stimulation
of normal human skin with these VFHs elicits a sensation of
painful pricking. A significant increase in the frequency of foot
withdrawals in response to this mechanical stimulation was
interpreted as mechanical hyperalgesia.
2. Cold allodynia. Behavioral responses to innocuous cold
stimulation were tested by the acetone drop test [23]. A 50 ml
droplet of acetone was applied to the unilateral mid-plantar hind
paw using a syringe connected to a thin polyethylene tube.
Acetone application was repeated ten times at intervals of
approximately 3 min between each application, and the number
of foot withdrawals was then counted. A brisk foot withdrawal
response after the spread of acetone over the plantar surface of the
paw was considered a sign of cold allodynia.
Sciatic nerve conduction velocities
Two weeks after BM-MNC transplantation, sciatic nerve
conduction velocities were measured. Rats were deeply anesthe-
tized with pentobarbital and placed on a heating pad in a room
maintained at 25uC to ensure a constant rectal temperature of
37uC. Motor nerve conduction velocity (MNCV) between the
ankle and sciatic notch, and sensory nerve conduction velocity
(SNCV) in the sciatic nerve between the ankle and knee were
measured using a non-invasive procedure. MNCV and SNCV
were determined with a Neuropak NEM-3102 instrument (Nihon-
Koden, Osaka, Japan) by methods described previously [24].
Sciatic nerve blood flow (SNBF)
Two weeks after BM-MNC transplantation, SNBF was
measured by the hydrogen clearance technique with an analog
recorder BW-4 (Biochemical Science, Kanazawa, Japan) and
electrolysis tissue blood flow meter RBA-2 (Biochemical Science,
Kanazawa, Japan), as described previously [25].
Capillary density in skeletal muscles
Two weeks after BM-MNC transplantation, rats were killed
with an overdose of pentobarbital. The soleus muscles of both hind
limbs were removed and fixed in a 4% paraformaldehyde solution
overnight. The fixed materials were embedded in paraffin and cut
into 5-mm sections for immunohistochemical staining with primary
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incubated overnight at 4uC with the primary antibody (anti-vWF
polyclonal antibody, DAKO Japan, Tokyo, Japan) diluted 1:600
and subsequently stained using the Simplestain rat system
(Nichirei, Tokyo, Japan) according to the manufacturer’s instruc-
tions. The negative control was performed by omitting anti-factor
VIII antibody. The capillary endothelial cells were counted under
light microscopy (6200) to determine the capillary density. To
avoid overestimating the capillary density due to muscle atrophy
or underestimating it due to interstitial edema, the capillary
density was expressed as the capillary/muscle fiber ratio.
mRNA expressions of skeletal muscles
Total RNA was extracted from the frozen samples of soleus
muscles using using TRIzol Reagent (Invitrogen, Carlsbad, CA),
according to the manufacturer’s instructions. Starting from 500 ng
RNA, cDNA was synthesized using ReverTra Ace (Toyobo,
Osaka, Japan), according to the manufacturer’s instructions.
Primers and probes for basic FGF, NT-3, and 18S rRNA for
the endogenous control were purchased from Taqman Gene
Expression Assays (Applied Biosystems, Foster City, CA). Real-
time quantitative PCR was performed and monitored using ABI
Prism 7000 (Applied Biosystems). Relative quantity was calculated
by the 2[DELTA]
[DELTA]ct method [26].
Intraepidermal nerve fiber density (IENFD)
IENFD was assessed as described previously with minor
modification [27]. Briefly, at the end of the experiments, rats
were sacrificed with an overdose of pentobarbital. Both footpads
were removed and fixed in a 4% paraformaldehyde solution
overnight. The fixed materials were embedded in paraffin and cut
into 5-mm sections. The sections were incubated overnight at 4uC
with the primary antibody (anti-PGP9.5 antibody, Abnova, Taipei
City, Taiwan) diluted 1:400 and subsequently stained using the
Simplestain rat system (Nichirei) according to the manufacturer’s
instructions. The negative control was performed by omitting anti-
PGP9.5 antibody. Intraepidermal nerve fiber profiles were
counted blindly by 3 independent investigators under light
microscopy (6200) and the average values were used.
Statistical analysis
All group values were expressed as means 6 standard error of
the mean (SEM). Two-way analysis of variance (ANOVA) with
repeated measures or one-way ANOVA, and Dunnett’s post-hoc
test were utilized to analyze the influence of STZ injection and
BM-MNC transplantation on pain behaviors, as appropriate.
Statistical analyses for other tests were made by one-way ANOVA
followed by the Bonferroni correction for multiple comparisons.
Differences were considered significant at the P,0.05 level.
Results
Changes in body weights gain and blood glucose
concentrations
Diabetic rats showed significant decreases in body weight gain
and significant increases in blood glucose concentrations compared
with normal rats (Table S1). The transplantation of BM-MNCs into
the unilateral hind limb skeletal muscles did not change the body
weights and blood glucose concentrations in the diabetic rats.
Effects of BM-MNCs on mechanical hyperalgesia
Figure 1 shows the effects of BM-MNC transplantation on
mechanical hyperalgesia in STZ-induced diabetic rats. Intraper-
itoneal administration of STZ elicited foot withdrawal with
significantly increased frequency in the diabetic control rats.
Namely, the number of foot withdrawals in response to the VFH
stimulation (93 and 197 mN) was significantly increased 2 weeks
after STZ injection, and the level remained high for another 3
weeks (93 mN: F(4,20)=3.73; 197 mN: F(4,20)=3.82, for both
P,0.05). This implies that STZ-induced diabetes shows long-
lasting mechanical hyperalgesia. In the BM-MNC transplanted
group, a significant increase in the withdrawal response 2 weeks
after STZ injection was also observed. Interestingly, the STZ-
induced increase in the withdrawal response was inhibited after
BM-MNC transplantation compared with that in the control
group (93 mN: group, F(1,12)=3.11, P.0.05; day, F(4,48)=6.96,
P,0.005; interaction, F(4,48)=0.48, P.0.05; 197 mN: group,
F(1,12)=5.89, P,0.05; day, F(4,48)=5.76, P,0.001; interaction,
F(4,48)=1.79, P.0.05), and the number of foot withdrawals
returned to the baseline level and stayed at this level afterwards
(93 mN: F(4,28)=3.72, P,0.05; 197 mN: F(4,28)=3.9, P,0.05).
These results indicate that BM-MNC transplantation alleviated
the persistence of mechanical hyperalgesia in diabetic rats.
Figure 2 shows the effects of BM-MNC transplantation in the
unilateral hindlimb muscles on mechanical hyperalgesia in the
bilateral hind paws of the diabetic rats. As shown in Figure 1, the
withdrawal frequencies of both bilateral hind paws to 93- and
197-mN VFH were significantly increased 2 weeks after STZ
injection (93 mN: ipsilateral: F(4,28)=2.76, P,0.05; contralateral:
F(4,28)=7.62, P,0.01; 197 mN: ipsilateral: F(4,28)=2.76, P,0.05;
contralateral: F(4,28)=7.62, P,0.01). After BM-MNC transplan-
tation, the STZ-induced increase in the withdrawal frequencies in
the ipsilateral side was significantly inhibited. On the other hand,
the withdrawal frequencies in the contralateral side remained at a
high level for another 3 weeks. Repeated measures two-way
ANOVA identified a significant difference in the day-effect
between both hind paws (93 mN: group, F(1,14)=11.7, P,0.005;
day, F(4,56)=6.96, P,0.001; interaction, F(4,56)=0.66, P.0.05;
197 mN: group, F(1,14)=1.95, P.0.05; day, F(4,56)=7.38,
P,0.001; interaction, F(4,56)=0.68, P.0.05). These results
indicate that BM-MNC transplantation in the unilateral hindlimb
muscles inhibited mechanical hyperalgesia only in the ipsilateral
hind paw of diabetic rats.
Effects of BM-MNCs on cold allodynia
The effects of BM-MNC transplantation on the cold allodynia
in the ipsilateral hind paw of diabetic rats are shown in Figure 3.
The number of foot withdrawals in response to the acetone
application in the diabetic control rats was significantly increased 2
weeks after STZ injection and remained high for another 5 weeks
(Saline group, F(4,36)=5.83, P,0.001), implying that STZ-induced
diabetes showed long-lasting cold allodynia. In the experimental
group of rats, BM-MNC transplantation was done 2 weeks after
the STZ injection. In this case, the increased withdrawal frequency
in the diabetic rats was reduced to the baseline level 5 weeks after
the transplantation (F(4,32)=3.55, P,0.05). These results indicate
that BM-MNC transplantation also ameliorated the persistence of
cold allodynia in diabetes, although the effect occurred later than
that of mechanical hyperalgesia.
Sciatic nerve conduction velocities
Four weeks after the STZ and saline injections, changes in
sciatic nerve conduction velocities in diabetic and normal rats were
measured. In the saline-injected side of the diabetic rats, MNCV
and SNCV were 36.462.6 m/s and 31.762.9 m/s, respectively,
which were significantly reduced compared with those in the
saline-injected side of normal rats (MNCV: 62.666.2 m/s,
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PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27458Figure 1. Inhibitory effects of BM-MNC transplantation on mechanical hyperalgesia induced by STZ administration. Number of foot
withdrawals in response to the 93 (A) and 197 mN (B) von Frey hair (VFH) stimulation in diabetic rats is shown. Data are presented as mean 6 SEM.
Vertical axis, number of foot lifts; horizontal axis, order of the test (weeks after STZ injection). Broken line shows the time point of STZ administration
and BM-MNC transplantation. In the treatment group (solid circles), BM-MNC injection was carried out just after the measurements at 2 weeks (2W)
after the STZ injection (n=8). In the control group (open circles), saline injection was done (n=6). Repeated measures two-way ANOVA identified a
significant difference in the day-effect between BM-MNC transplanted and control group. *P,0.05 compared with before (B) STZ injection (one-way
ANOVA with Dunnett’s tests).
doi:10.1371/journal.pone.0027458.g001
Figure 2. BM-MNC transplantation inhibited mechanical hyperalgesia in the ipsilateral diabetic hind paw. Number of foot withdrawals
in response to the 93 (A) and 197 mN (B) von Frey hair (VFH) stimulation in both hind paws of diabetic rats are shown (n=8). Data are presented as
mean 6 SEM. The form of presentation is the same as in Fig. 1. BM-MNC injection was carried out just after the measurements at 2 weeks (2W) after
the STZ injection. Repeated measures two-way ANOVA identified a significant difference in the day-effect between both hind paws. *P,0.05
compared with before (B) STZ injection (one-way ANOVA with Dunnett’s tests).
doi:10.1371/journal.pone.0027458.g002
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rats, both MNCV and SNCV in the BM-MNC-injected side
were significantly ameliorated (MNCV: 51.460.8 m/s, SNCV:
47.563.6 m/s). Transplantation of BM-MNCs in normal rats did
not affect the sciatic nerve conduction velocities.
Sciatic nerve blood flow (SNBF)
Changes in SNBF in diabetic and control rats were also
measured 4 weeks after the STZ and saline injections. As shown in
Figure 5, SNBF was significantly decreased in the saline-injected
side of diabetic rats (9.861.1 ml/min/100 g) compared with those
in the saline-injected side of normal rats (19.262.5 ml/min/
100 g, P,0.05), indicating that SNBF was decreased in the
diabetic condition. In diabetic rats, SNBF in the BM-MNC-
injected side (16.961.3 ml/min/100 g) was significantly increased
compared with that in the saline-injected side (P,0.01).
Transplantation of BM-MNCs in normal rats did not show
significant changes of SNBF.
Capillary density of skeletal muscles
Vasculatures were visualized by vWF immunostaining, a
specific marker for endothelial cells. As shown in Figure 6A, the
capillary density was reduced in the saline-injected side of the
diabetic rats. Quantitative analyses revealed that the capillary/
muscle ratio in the saline-injected side of diabetic rats was
significantly reduced compared with that in the saline-injected side
of normal rats (Figure 6B, P,0.001). In diabetic rats, transplan-
tation of BM-MNCs significantly increased the number of
capillaries in skeletal muscles compared with those in the saline-
injected side (P,0.001). Transplantation of BM-MNCs in normal
rats did not affect the capillary/muscle ratio.
Local gene expressions in skeletal muscles
The mRNA expression of NT-3 was significantly decreased in
saline-injected side of the soleus muscles of diabetic rats (P,0.05)
(Figure 6C). BM-MNC transplantation significantly increased the
NT-3 mRNA expressions by 1.7 times compared with the saline-
injected side of diabetic rats (P,0.05). BM-MNC transplantation
tends to increase the bFGF mRNA expressions in the transplant-
ed-side of diabetic rats, although the increase was not significant.
Intraepidermal nerve fiver density (IENFD)
Nerve fibers were visualized by PGP9.5 immunostaining, a
specific neuronal marker (Figure 7A). Quantitative analyses
revealed that IENFD in the saline-injected side of the diabetic
rats was significantly reduced compared with that in the saline-
injected side of normal rats (saline-injected side of diabetic rats:
17.961.3/mm, saline-injected side of control rats: 22.461.3/mm,
P,0.05) (Figure 7B). This implies that the 4-week duration of
diabetes decreased the intraepidermal nerve fiber profiles
(IENFD). BM-MNC transplantation tended to increase the
IENFD in diabetic rats, but the change was not significant. BM-
MNC transplantation had no significant effect in normal rats.
Discussion
The present study first demonstrated that the transplantation of
freshly isolated BM-MNCs into the hindlimb skeletal muscles
alleviated the persistence of neuropathic pain (mechanical
hyperalgesia and cold allodynia) in diabetic rats. The BM-MNC
transplantation also improved the delay of sciatic nerve conduc-
tion velocities (MNCV and SNCV) in the diabetic rats. Our
results, therefore, suggest that the transplantation of isolated BM-
MNCs into the hindlimb skeletal muscles ameliorated the diabetic
neuropathic pain as a result of the rescue of neural functions.
Painful diabetic neuropathy reduces the quality of life in
diabetic patients. Most pharmacological managements of painful
diabetic neuropathy are intended to provide relief from pain
without any effects on the underlying causes and, in many cases,
clinicians provide these pharmacological agents for relief from
pain [28]. The symptoms are commonly described as prickling,
knife-like, electric shock-like, burning, freezing together with
hyperalgesia and allodynia [1]. Here, we demonstrated that BM-
MNC transplantation ameliorated diabetic hyperalgesia and cold
allodynia together with improvement of the nerve functions. Our
results suggest that BM-MNC transplantation could become a new
strategy for treating diabetic neuropathy.
Impairment of peripheral blood flow is one of the major factors
in diabetic neuropathy. Our present study showed that the
capillary/muscle ratio in the soleus muscle was significantly lower
in the diabetic rats compared with normal rats, which is consistent
with previous animal and human studies [19,29]. The immuno-
histological study revealed that the BM-MNC transplantation
increased the number of microvessels in the ipsilateral soleus
muscle. In the sciatic nerve, STZ-induced diabetes induced a
reduction of the nerve blood flow and this deficit was recovered by
BM-MNC transplantation. Kim et al. indicated that transplanted
BM-MNCs preferentially engrafted in the sciatic nerve and
improved nerve blood flow [22]. These results, therefore, suggest
that improvement of the blood flow in the tissues including nerve
vessels is one of the crucial effects of BM-MNC transplantation.
Clinical trials of the transplantation of MNCs have mainly been
conducted for the rescue of ischemic tissues, such as from
Figure 3. Inhibitory effects of BM-MNC transplantation on cold
allodynia induced by STZ administration. Number of foot
withdrawals in response to the acetone application in diabetic rats is
shown. Data are presented as mean 6 SEM. Vertical axis, number of
foot lifts; horizontal axis, order of the test (weeks after STZ injection).
Black column, before STZ injection; white column, 2 weeks after STZ
injection; shadow column, 3, 5, and 7 weeks after STZ injection. In the
treatment group (left panel), BM-MNC injection was carried out just
after the measurements at 2 weeks after the STZ injection (n=9). In the
control group (right panel), saline injection was done (n=10). *P,0.05
compared with before (B) STZ injection (one-way ANOVA with
Dunnett’s tests).
doi:10.1371/journal.pone.0027458.g003
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has been demonstrated that one of the mechanisms mediating the
effects of MNC transplantation is the collateral formation in the
ischemic tissue by the abundant secretion of cytokines, such as
VEGF and bFGF, that play a crucial role in neovascularization
[31]. Our present study showed that transplantation of BM-MNCs
into the unilateral hindlimb skeletal muscles inhibited mechanical
hyperalgesia in the ipsilateral side but not in the contralateral side.
Two clinical studies supported these observations linking painful
diabetic neuropathy with alterations in blood flow, and demon-
strated significant benefits of pain relief from the use of
vasodilators, isosorbide dinitrate spray, and glyceryl trinitrate
patches [32,33].
bFGF is also a neuroprotective cytokine [34,35], and we
previously revealed that intramuscular injection of bFGF with
cross-linked gelatin hydrogel improved the sciatic nerve conduc-
tion velocity, hypoalgesia, and sciatic nerve blood flow in STZ-
induced diabetic rats [36]. In this study, we demonstrated that
BM-MNC transplantation increased the gene expressions of bFGF
and NT-3 in the BM-MNC-transplanted site of skeletal muscles in
diabetic rats. NT-3 works as neurotrophic factor [37]. A previous
study reported the reduction of chronic constriction injury-
induced neuropathic pain by the attenuation of neuronal
expression of the sodium channel [38]. A previous report revealed
that transplantation of BM-MNCs into diabetic hindlimb skeletal
muscles increased several gene expressions such as VEGF, bFGF
and IGF-1 in sciatic nerve. IGF-1 is also reported to ameliorate
neuropathic pain and diabetic hyperalgesia [39]. A recent study
revealed that BM-MNC transplantation into ischemic heart
normalized more than 2099 genes altered by myocardial infarction
and changed more than 200 gene expressions which were
independent of ischemia using microarray analysis, indicating
that BM-MNC transplantation affects many gene expressions [40].
These results suggest that the effects of BM-MNC transplantation
on diabetic hyperalgesia and allodynia are achieved not by a single
mechanism, but by multifocal mechanisms depending on changes
in growth factors, neurotrophic factors and other multiple gene
expressions.
It is interesting that there is a difference in the onset of efficacy
on mechanical hyperalgesia and cold allodynia by BM-MNC
transplantation. BM-MNCs ameliorated mechanical hyperalgesia
within 1 week after transplantation, whereas, it took 5 weeks to
improve cold allodynia after transplantation. This discrepancy in
the efficacy is often observed in the treatment of painful diabetic
neuropathy [41,42]. Several human and animal studies demon-
strated that small unmyelinated (C) fibers and thinly myelinated
(A-d) fibers as well as myelinated large (A-b) fibers, are damaged in
the diabetic neuropathic condition [43,44]. Our skin biopsy study
revealed that IENFD in the footpad, indicating the amount of C
fiber sensory units [45], was decreased 4 weeks after the induction
of diabetes, whereas both mechanical hyperalgesia and cold
allodynia continued. These results indicate that these painful
behaviors were not due to decreased IENFD (i.e., C-fibers), but to
Figure 4. Effects of BM-MNC transplantation on sciatic motor nerve conduction velocity and sensory nerve conduction velocity. BM-
MNCs were transplanted into unilateral hindlimb skeletal muscles 2 weeks after the STZ injection, and sciatic motor nerve conduction velocity (MNCV)
and sensory nerve conduction velocity (SNCV) were measured 2 weeks later. Results are means 6 SEM. *P,0.001 vs. saline-injected side of control
rats. **P,0.01 vs. saline-injected side of diabetic rats.
doi:10.1371/journal.pone.0027458.g004
Figure 5. Effects of BM-MNC transplantation on sciatic nerve
blood flow (SNBF). BM-MNCs were transplanted into unilateral
hindlimb skeletal muscles 2 weeks after the STZ injection, and SNBF was
measured 2 weeks later. Results are means 6 SEM. *P,0.05 vs. saline-
injected side of control rats. **P,0.01 vs. saline-injected side of diabetic
rats.
doi:10.1371/journal.pone.0027458.g005
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27458functional changes in the nerve fibers. We previously found in in
vitro experiments using skin-saphenous nerve preparations taken
from rats in the early stage of STZ-induced diabetes that C-fiber
nociceptors in the skin showed increased spontaneous activity and
a lowered response threshold to mechanical stimulation under
perfusion with high-glucose solution [46]. In normal rats, on the
other hand, these augmenting effects of high-glucose were not
observed. These results suggest that C-fiber nociceptors that had
been spared serious damage by the diabetes play an important role
in the aggravation of pain in diabetic neuropathy. Fuchs et al.
revealed that sensory and neurosecretory nociceptor functions are
sensitized in diabetic rats and hyperglycemia with hypoxia
increased the sensitivity of diabetic C-fibers more than hypergly-
cemia alone [47] suggesting that not only the correction of
diabetes but also the recovery from hypoxia is a valuable target for
the treatment of painful diabetic neuropathy. On the other hand,
it has been demonstrated that hypersensitivity to mechanical
stimulation persisted even when C-fiber responses were abolished
with resiniferatoxin [48]. This indicates that hypersensitivity to
mechanical stimulation in diabetic rats is mediated by larger
myelinated (A-b and A-d) fibers rather than by C-fibers. The fact
that vasodilator treatment or drugs that increase the nerve blood
flow ameliorated pain-related behaviors and improved the slowed
nerve conduction velocity [49,50] may indicate that larger
myelinated (A-b and A-d) fibers might also play an important
role in diabetic pain. Taken together, the multifocal efficacy of
BM-MNC transplantation may be a favorable treatment for
painful diabetic neuropathy.
An important benefit of BM-MNC transplantation is that BM-
MNCs can be isolated in a closed cavity, in contrast to endothelial
progenitor cells and mesenchymal stem cells that require ex vivo
culture. Clinical trials for ischemic diseases using BM-MNCs
revealed their safety and efficiency [15,16]. However, future
clinical study is required to identify the effects of BM-MNC
transplantation on painful diabetic neuropathy.
We did not evaluate the effects of BM-MNC transplantation on
neuropeptides in our study. We investigated diabetic hyperalgesia
in the early stage diabetic neuropathy. We evaluated each
measurement around 4 weeks after STZ injection in SD rats. A
previous report revealed that the basal levels of neuropeptides such
as calcitonin gene-related peptide (CGRP), substance P (SP) and
prostaglandin E2 (PGE2) were reduced or not changed between
the control and diabetic hyperalgesia group, but greater release of
these pain-related peptides was observed by chemical stimulation
with bradykinin in a diabetic skin-nerve preparation than in
control [51]. In addition, we showed mechanical hyperalgesia and
cold allodynia without an increase of the nerve fiber density in the
skin. These results suggest that the neural hypersensitivity is the
main phenomenon in the early stage of diabetic neuropathy,
though further study is required to address this question.
Figure 6. Capillary density and gene expressions in skeletal muscles. A: Representative photomicrographs of histological sections in the
saline-injected and BM-MNC-injected sides of the skeletal muscles of normal and diabetic rats. Arrowheads indicate vascular endothelial cells
detected by immunostaining for vWF. Bar=50 mm. B: Quantitative analyses for capillary/muscle fiber ratio of the saline-injected and BM-MNC-
injected sides of the skeletal muscles in normal and diabetic rats. Results are means 6 SEM. *P,0.001 vs. saline-injected side of control rats.
**P,0.001 vs. saline-injected side of diabetic rats. C: bFGF and NT-3 mRNA expressions in saline and BM-MNC-injected muscle. Results are means 6
SEM. *P,0.05 vs. saline-injected side of control rats. **P,0.05 vs. saline-injected side of diabetic rats.
doi:10.1371/journal.pone.0027458.g006
MNC Transplantation Improves Diabetic Pain
PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27458In summary, we demonstrated that the transplantation of BM-
MNCs ameliorated the diabetic neuropathic pain, caused
functional recovery of the peripheral nerves and increased nerve
blood flow. To our knowledge, this is the first report that BM-
MNC transplantation ameliorated mechanical hyperalgesia and
cold allodynia in diabetic neuropathy. The autologous transplan-
tation of BM-MNCs could be a novel strategy for the treatment of
painful diabetic neuropathy.
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